A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.

Trial Profile

A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 May 2015

At a glance

  • Drugs Axitinib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Jun 2012 Company added in the association field as reported by EudraCT.
    • 08 Dec 2011 Status changed from completed to discontinued according to Pfizer and ClinicalTrials.gov description.
    • 08 Feb 2011 Results published in the Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top